ADAR1 Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

ADAR1 Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.53M	Hold	38,566	–	–	0.09%	132
2025 Q4	$965K	Sell	38,566 -15,100	-28%	-$382K	0.07%	134
2025 Q3	$1.3M	Sell	53,666 -243,100	-82%	-$4.32M	0.12%	95
2025 Q2	$3.9M	Buy	296,766 +80,600	+37%	+$1.02M	0.6%	40
2025 Q1	$3.11M	Buy	216,166 +62,139	+40%	+$1.02M	0.58%	48
2024 Q4	$2.58M	Buy	154,027 +130,725	+561%	+$2.17M	0.52%	43
2024 Q3	$373K	Sell	23,302 -229,895	-91%	-$2.82M	0.06%	130
2024 Q2	$2.29M	Buy	253,197 +46,341	+22%	+$440K	0.43%	39
2024 Q1	$2.34M	Buy	+206,856	New	+$1.96M	0.53%	37

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ADAR1 Capital Management's CNTA Position: Q1 2026 in Review

ADAR1 Capital Management held its Centessa Pharmaceuticals (CNTA) position steady in Q1 2026 at 38,566 shares worth $1.53M. The position accounts for 0.09% of the portfolio, ranked #132.

ADAR1 Capital Management first reported a position in CNTA in Q1 2024 and has held it in 9 quarters since. The position peaked at $3.9M in Q2 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

ADAR1 Capital Management held 38,566 shares of Centessa Pharmaceuticals worth $1.53M as of Q1 2026.
ADAR1 Capital Management left its Centessa Pharmaceuticals share count unchanged in Q1 2026.
Centessa Pharmaceuticals made up 0.09% of ADAR1 Capital Management's portfolio in Q1 2026, its #132 holding.
ADAR1 Capital Management first reported a position in Centessa Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
ADAR1 Capital Management's Centessa Pharmaceuticals position peaked at $3.9M in Q2 2025.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.